TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17651679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Crystalens and ReSTOR
Study: 15716155
Drug: Levodopa (L-dopa)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa (L-dopa) medication
Study: 15716155
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (off L-dopa)
Study: 11881867
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml air injection
Study: 11881867
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml air injection
Study: 11881867
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml air injection
Study: 11881867
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml air injection
Study: 11881867
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml air injection
Study: 11881867
Drug: ≥4 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥4 ml air injection
Study: 1672634
Drug: Metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol sulfate (1.95 mg)
Study: 7189485
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg miconazole once daily for 6 days (A)
Study: 7189485
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg miconazole once daily for 3 days (B)
Study: 28290274
Drug: Individual tablets
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual tablets
Study: 24143910
Drug: Multipurpose contact
Normalized name: CONTACT LENS SOLN (BIOTRUE MULTIPURPOSE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multipurpose contact lens solution/silicone hydrogel lens combination (renu® fresh™ and balafilcon A)
Study: 23268177
Drug: Hydrodynamic irrigation
Normalized name: Carbamyl hydroxamate
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrodynamic irrigation with laser root canal therapy (number of patients not specified)
Study: 23268177
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal treatment (51 patients)
Study: 19514448
Drug: Vobenzyme added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vobenzyme added to standard antibiotic therapy
Study: 17623763
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (FAC protocol: 5-fluorouracil, adriamycin, and cyclophosphamide)
Study: 17623763
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC protocol: adriamycin and cyclophosphamide)
Study: 17623763
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CMF protocol: cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 17623763
Drug: All chemotherapy
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All chemotherapy protocols
Study: 1319870
Drug: Crushed tablet
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablet with enteral feeding solution (Osmolite 100 ml/h started 2h before administration and continued for 4h postdose)
Study: 1319870
Drug: Crushed tablet
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablet without enteral feeding solution
Study: 1319870
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet (reference)
Study: 29396806
Drug: Flexion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexion group (knee at 90° flexion for 12 hours, then 60° for 12 hours, combined with 1g TXA topical and 1g TXA intravenous)
Study: 29396806
Drug: Extension group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extension group (knee in full extension, combined with topical and intravenous TXA)
Study: 29396806
Drug: Controlled group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled group (knee in full extension, combined with single intravenous TXA)
Study: 19007042
Drug: lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine (150 mg)
Study: 19007042
Drug: stavudine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: stavudine (40 mg)
Study: 19007042
Drug: nevirapine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: nevirapine (200 mg)
Study: 16614435
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement with vitamin A
Study: 12664066
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of lidocaine in the periprostatic nerves
Study: 10857841
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) adjunctive treatment
Study: 21422479
Drug: Subantimicrobial-dose doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subantimicrobial-dose doxycycline (SDD)
Study: 8967667
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone, 0.1 mg/kg of body weight per day (average dosage, 6 mg/d) for 12 weeks
Study: 8967667
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone and Placebo
Study: 1653773
Drug: BW 91Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW 91Y (3‐deazaadenosine) at 600 pg/ml
Study: 6142508
Drug: Oral almitrine
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral almitrine 200 mg/day
Study: 30839430
Drug: Loxoprofen sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen sodium topical patch (LX-P)
Study: 30839430
Drug: Loxoprofen tablet
Normalized name: loxoprofen
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen tablet (LX-T)
Study: 28679073
Drug: Cancer Carers
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer Carers Medicines Management (CCMM)
Study: 25211703
Drug: Resveratrol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplementation (150 mg)
Study: 22356705
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of neutral 0.025% sodium fluoride rinse (group II)
Study: 22356705
Drug: Tooth mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth mousse twice a day in addition to fluoride toothpaste for 6 months (group III)
Study: 17080442
Drug: Methylphenidate (MP)
Normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MP) 0.25 mg/kg
Study: 11829722
Drug: Salvage antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage antiretroviral therapy (specific agents not detailed)
Study: 11829722
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents and new classes of drugs in salvage therapy
Study: 9810992
Drug: Silicone occlusive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone occlusive gel (Epiderm) used in 61 patients
Study: 2648927
Drug: Methylprednisolone (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (32 mg)
Study: 1103271
Drug: Diphenoxylate 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenoxylate 5 mg three times daily
Study: 8838189
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid complex (ABLC) at 1.2-5.0 mg/(kg.d) for 6 weeks
Study: 8838189
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AmB) at 0.7-1.2 mg/(kg.d) for 6 weeks
Study: 28523988
Drug: Myofascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial therapy (8 sessions from 2 to 4 months post-surgery)
Study: 28523988
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy programme
Study: 12645187
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow supplemental oxygen therapy
Study: 9594864
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 10) - CPB circuit without treatment
Study: 7542804
Drug: AZT-3TC combination
Normalized name: zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZT-3TC combination therapy
Study: 2466351
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (S)
Study: 80528
Drug: Cephalothin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin and gentamicin (C.G.)
Study: 80528
Drug: Methicillin and
Normalized name: methicillin
DrugBank: Meticillin (DB01603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methicillin and gentamicin (M.G.)
Study: 80528
Drug: Combined cephalothin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cephalothin groups (C.G. and C.T.)
Study: 80528
Drug: Combined methicillin
Normalized name: methicillin
DrugBank: Meticillin (DB01603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined methicillin groups (M.G. and M.T.)
Study: 31345981
Drug: Masculinity Barriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masculinity Barriers to Care Scale (MBCS) administered as an online quantitative survey.
Study: 26951379
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg every 2 weeks)
Study: 21277394
Drug: Budesonide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (0.25 mg twice daily)
Study: 19799571
Drug: Interactive Voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Voice Response (IVR) system with varying call schedules (weekly, biweekly, monthly)
Study: 15696287
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of dilute lidocaine (40 mg in 6.0 ml, 3.0 ml for each side or 4.0 and 2.0 ml for two sides)
Study: 15696287
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (6.0 ml) as a placebo
Study: 12475460
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE), 0.625 mg
Study: 12475460
Drug: Transdermal estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estradiol, 0.1 mg/day
Study: 12475460
Drug: Oral CEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CEE
Study: 28910185
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy intervention for smoking cessation over six weeks.
Study: 23173246
Drug: bushui roumu
Approvals — FDA: no, EMA: no, PMDA: no
Description: bushui roumu recipe (BRR) combined with medroxyprogesterone acetate tablet (MAT)
Study: 23173246
Drug: artificial period
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: artificial period method (Western medicine group)
Study: 15975301
Drug: Futalin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futalin tablets (diclofenac sodium)
Study: 12474115
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg, PO)
Study: 7751433
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg daily
Study: 1969172
Drug: Bromazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (3 mg, two daily doses)
Study: 1969172
Drug: Chlorprothixene (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorprothixene (15 mg, two daily doses)
Study: 351848
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone or prednisolone (30 mg/day)
Study: 28952191
Drug: Oral lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipid tolerance test (OLTT)
Study: 21866656
Drug: Routine progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Routine progesterone treatment after laparoscopic surgery
Study: 19196362
Drug: Multiple drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drugs
Study: 16924049
Drug: Low-dose acitretin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acitretin (25 mg/d)
Study: 16924049
Drug: High-dose acitretin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acitretin (50 mg/d)
Study: 15054734
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (VE) oil solution rinse before and after radiotherapy
Study: 15054734
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil solution rinse before and after radiotherapy
Study: 15054734
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (VE) oil solution rinse
Study: 10443771
Drug: Saccharin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharin (50 mg)
Study: 8198625
Drug: calcium (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium (800 mg/day) + vitamin D3 placebo
Study: 30514434
Drug: Visual Schema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual Schema Displacement Therapy (VSDT)
Study: 28403360
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1.23% acidulated phosphate fluoride (APF)
Study: 23635560
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of paclitaxel, carboplatin, and trastuzumab (12 doses over 16 weeks)
Study: 23635560
Drug: Every-3-weeks administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every-3-weeks administration of paclitaxel, carboplatin, and trastuzumab (4 doses over 12 weeks)
Study: 23635560
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration in luminal-B (HER2-positive) tumors
Study: 23635560
Drug: Every-3-weeks administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every-3-weeks administration in luminal-B (HER2-positive) tumors
Study: 23635560
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration in ERBB2+ tumors
Study: 23635560
Drug: Every-3-weeks administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every-3-weeks administration in ERBB2+ tumors
Study: 18505646
Drug: Dyract with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyract with prior nonrinse conditioner (NRC) treatment and bonding with Prime&Bond NT
Study: 18505646
Drug: Polyacid-modified resin
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyacid-modified resin composite (F2000) in conjunction with a self-etch adhesive (Prompt-L-Pop, 3M/ESPE)
Study: 17172172
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with a complex containing Ester-C with antioxidants (2100 mg of Ca-ascorbate + 340 mg of bioflavonoids)
Study: 11155094
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR (3 injections at 4 week intervals)
Study: 11155094
Drug: Lanreotide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (5 injections at 14 day intervals)
Study: 1491345
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of moxisylyte
Study: 8103112
Drug: Intracavernous administration
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous administration of moxisylyte
Study: 3756776
Drug: Chemotherapy (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cyclophosphamide, vincristine, and prednisone [CVP], five courses)
Study: 29390245
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron therapy with sodium ferrigluconate
Study: 26903081
Drug: Mind-body program
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body program (8-week group program followed by 6 monthly sessions)
Study: 23377510
Drug: Dapsone 5%
Normalized name: DAPSONE 5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 5% gel
Study: 15593011
Drug: 2-dose IPT
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose IPT with SP
Study: 15593011
Drug: weekly CQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly CQ chemoprophylaxis
Study: 15593011
Drug: 2-dose IPT
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose IPT with CQ
Study: 11834680
Drug: Prednisone, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 60 mg/d for 7 days
Study: 11207478
Drug: Gelatine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine 4% (GEL)
Study: 11207478
Drug: Hydroxyethylstarch solution
Normalized name: hydroxyethylstarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylstarch solution 6% (HES)
Study: 9408699
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (750 mg twice a day for 3 months)
Study: 8487654
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration prior to FSIGT
Study: 8487654
Drug: Saline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administration prior to FSIGT
Study: 3104750
Drug: TRH (thyrotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (thyrotropin-releasing hormone) at 10 mg per kg on alternate days for 3 months
Study: 3102991
Drug: TRH (thyrotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (thyrotropin-releasing hormone)
Study: 22315336
Drug: Adjuvanted 3.75-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted 3.75-μg HA/AS03(A)
Study: 22315336
Drug: Adjuvanted formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted formulation (2 doses) or 1 dose of adjuvanted 3.75-μg HA formulation
Study: 14671904
Drug: Plapherone LB
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plapherone LB (sublingually, 2 mg protein/day)
Study: 14671904
Drug: Routine intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine intensive therapy
Study: 10804025
Drug: Human parathyroid
Normalized name: HUMAN PARATHYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human parathyroid hormone 1-34 (hPTH(1-34)) daily injections for 12 months
Study: 10804025
Drug: Human parathyroid
Normalized name: HUMAN PARATHYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human parathyroid hormone 1-34 (hPTH(1-34))
Study: 8956699
Drug: Serum CA
Normalized name: Serum carnosinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CA 125 concentration > or = 30 U/ml
Study: 8956699
Drug: Serum CA
Normalized name: Serum carnosinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CA 125 concentration > 100 U/ml
Study: 8956699
Drug: Serum CA
Normalized name: Serum carnosinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CA 125 concentration < 30 U/ml
Study: 1658962
Drug: 1500 aPTT-U
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 aPTT-U low-molecular-weight heparin plus 0.5 mg dihydroergotamine (Embolex)
Study: 1658962
Drug: twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily administration of 5000 IU of the heparin-dihydroergotamine combination (Heparin-Dihydergot)
Study: 23838709
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (group T)
Study: 20041778
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng extract-containing herbal mixture at 3 g/day
Study: 15764166
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg daily for 5 days, repeated 3 times with a 23-day interval
Study: 2616205
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine-gum (8-12 gums a day for one month)
Study: 310339
Drug: Combined adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined adjuvant immunotherapy (bacillus Calmette‐Guérin and levamisole)
Study: 30587963
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for AECOPD
Study: 25447602
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (LDK) infusion (0.2 to 0.4 mg/kg, administered over 10 to 15 minutes)
Study: 25447602
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (LDK) infusion
Study: 9264500
Drug: Perindoprilat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat (5 nmol/mL)